A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Various Doses of ZT006 in Overweight and Obese Participants
Latest Information Update: 21 Nov 2025
At a glance
- Drugs ZT 006 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors QL Biopharmaceutical
Most Recent Events
- 21 Nov 2025 New trial record